首页|溶酶体半乳糖脑苷酯酶的作用机制及疾病

溶酶体半乳糖脑苷酯酶的作用机制及疾病

扫码查看
溶酶体贮积症(lysosomal storage diseases,LSD)是一类遗传性代谢障碍疾病,其发病机制主要源于溶酶体酸性水解酶的基因突变,导致酶的功能缺陷,进而触发生物大分子在溶酶体内的异常积累,继而对细胞、组织及器官功能造成显著损害。β-半乳糖脑苷酯酶(galactocerebrosidase,GALC)的突变或缺失导致鞘氨醇半乳糖苷(galactosylsphingosine)的累积,造成了进行性的脱髓鞘病变,诱发神经鞘脂贮积症-克拉伯病(Krabbe disease),其在疾病调控中的具体机制尚未完全阐明。目前,越来越多的有关GALC基因的致病突变被报道,结合GALC蛋白的三维结构解析,已逐渐了解GALC蛋白的突变造成克拉伯病的机制,这将为开发相关治疗药物提供有力的证据。此外,GALC在不同的肿瘤进程中扮演着双重角色,一些癌症中充当着抑癌因子的作用,而在另一些癌症中则发挥着致癌因子的作用,然而剖析GALC对癌症的影响仍需进一步深入的研究,这将为GALC作为潜在的肿瘤促进或抑制的靶点提供借鉴。GALC还与多种神经退行性疾病,包括阿尔茨海默病、帕金森氏病以及多发性硬化症有关。由于GALC作用机制的复杂性,目前,针对GALC缺乏所致的克拉伯病的治疗主要通过单一模式疗法(single-modality therapies)及多模式疗法(multi-modality therapies),但要开发出真正有效的治疗方法,仍需深入研究GALC基因缺陷导致的发病机制。本文综述了GALC的结构和功能特性,汇总并讨论了其在神经系统及肿瘤发生发展中的作用及相关研究的最新进展,旨在为未来深入探讨GALC的调控机制及开发治疗相关疾病的创新药物提供理论基础和参考。
Lysosomal Galactocerebrosidase-Mediated Lysosomal Regulation and Pathogenesis
Lysosomal storage diseases(LSD)are a category of genetic metabolic disorders,originating from genetic mutations in lysosomal acid hydrolases,leading to enzymatic deficiencies.Consequently,this triggers an abnormal accumulation of biological macromolecules within lysosomes,subsequently causes significant damage to cellular,tissue,and organ functions.Mutations or deficiencies in β-galactocerebrosidase(GALC)result in the accumulation of psychosine,causing progressive demyelination and triggering Krabbe Disease,a form of neurodegenerative lysosomal storage disease.The specific mechanisms involved in disease regulation are not yet fully elucidated.Increasing reports of pathogenic mutations in the GALC gene,coupled with analyses of GALC protein structure,have gradually enhanced the understanding of how GALC mutations contribute to Krabbe Disease.This knowledge offers robust evidence for the development of potential therapeutic drugs.Furthermore,GALC plays a dual role in various tumor processes,acting as a tumor suppressor in some cancers while acting as a carcinogen in others.However,a comprehensive analysis of GALC's impact on cancer requires further in-depth research,offering insight into GALC as a potential target for tumor promotion or suppression.GALC is also associated with various neurodegenerative diseases,including Alzheimer's disease,Parkinson's disease,and multiple sclerosis.Due to the complexity of GALC's mechanisms,current treatments for Krabbe Disease caused by GALC deficiency primarily involve single-modality and multi-modality therapies.Nevertheless,developing truly effective treatments necessitates deeper research into the pathogenic mechanisms arising from GALC gene defects.This review summarizes the structural and functional characteristics of GALC,and discusses its roles in the development of the nervous system and tumorigenesis,as well as the latest advances in related research.The aim is to lay the theoretical foundation and provide references for exploring GALC's regulatory mechanisms and developing innovative drugs for treating associated diseases in the future.

β-galactocerebrosidase(GALC)Krabbe diseasecancer

沈畅、尹秋媛、孟明耀、孙建伟

展开 >

云南大学生命科学中心,云南省细胞代谢与疾病重点实验室,省部共建云南生物资源保护与利用国家重点实验室,生命科学学院,昆明 650500

昆明市延安医院,云南省肿瘤免疫防治研究重点实验室,昆明 650051

β-半乳糖脑苷酯酶 克拉伯病 癌症

国家自然科学基金云南省肿瘤免疫防治研究重点实验室开放基金云南大学科研创新项目云南大学科研创新项目

82273460KLTIPT-2023-02KC-23233927ZC-23236399

2024

中国生物化学与分子生物学报
中国生物化学与分子生物学会 北京大学

中国生物化学与分子生物学报

CSTPCD北大核心
影响因子:0.617
ISSN:1007-7626
年,卷(期):2024.40(4)
  • 67